☆ 4.3 Article

Breakthrough SARS-CoV-2 infections after COVID-19 immunization

JOURNAL OF INVESTIGATIVE MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study

Po Ying Chia et al.

Summary: This study found that mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with a faster decline in viral RNA load and a robust serological response.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Immunology

Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening

Aaron J. Tande et al.

Summary: This study found a significant association between vaccination with mRNA-based COVID-19 vaccines and reduced risk of asymptomatic SARS-CoV-2 infection.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Letter Medicine, General & Internal

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose

Constanze Kuhlmann et al.

LANCET (2022)

Add to Collection

News Item Multidisciplinary Sciences

THE OMICRON WAVE'S SURPRISING LESSONS FOR LONG-TERM IMMUNITY

Cassandra Willyard

NATURE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Editorial Material Immunology

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine-Breakthrough Infection Phenotype Includes Significant Symptoms, Live Virus Shedding, and Viral Genetic Diversity

Simon D. Pollett et al.

Summary: This study characterizes 24 vaccine-breakthrough infections in mostly young healthy individuals, finding that while none required hospitalization, some experienced severe symptoms and shed high levels of live virus. The infecting genotypes included variant-of-concern (VOC) and non-VOC strains.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021

Brechje de Gier et al.

Summary: The study estimated the effectiveness of SARS-CoV-2 vaccines against onward transmission during the dominance of the Delta variant, finding that full vaccination of the index case resulted in 63% effectiveness against transmission to unvaccinated household contacts and 40% effectiveness against transmission to fully vaccinated contacts. This is in addition to the direct protection provided by vaccination of the contacts against infection.

EUROSURVEILLANCE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination

Michael Klompas

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Mark W. Tenforde et al.

Summary: This study evaluated the association between mRNA COVID-19 vaccines and COVID-19 hospitalization, as well as disease progression to critical illness among hospitalized patients. The results showed that vaccination with mRNA COVID-19 vaccines significantly decreased the likelihood of COVID-19 hospitalization and disease progression to death or mechanical ventilation.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

News Item Multidisciplinary Sciences

OMICRON LIKELY TO WEAKEN COVID VACCINE PROTECTION

Ewen Callaway

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant

Paul Elliott et al.

Summary: During early summer 2021, the Real-time Assessment of Community Transmission-1 (REACT-1) study in England found that infections were rising due to the Delta variant, with unvaccinated individuals having three times the prevalence of infection compared to double-vaccinated individuals. Despite vaccination, the vaccine effectiveness for double-vaccinated individuals was estimated to be around 50% to 60% during this period. Increased social mixing in the presence of the Delta variant had the potential to generate sustained growth in infections, even with high levels of vaccination.

SCIENCE (2021)

Add to Collection

Review Medicine, Research & Experimental

Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines

Wagner Gouvea Dos Santos

Summary: Despite global efforts, there are still many challenges and unanswered questions in the search for an effective way to prevent the spread of COVID-19. Scientists are currently debating issues such as reinfection of recovered individuals, duration of immunity, and the potential impact of mutations on the efficacy of vaccines. Ongoing clinical trials for various vaccines remain hopeful, but definitive conclusions on safety and efficacy will require further time and research.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Catherine H. Bozio et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Victoria Jane Hall et al.

Summary: This study investigated whether antibodies against SARS-CoV-2 were associated with a decreased risk of symptomatic and asymptomatic reinfection. It found that individuals with a previous history of SARS-CoV-2 infection had an 84% lower risk of reinfection, with a median protective effect lasting for 7 months following primary infection.

LANCET (2021)

Add to Collection

Editorial Material Immunology

COVID-19 vaccine decisions: considering the choices and opportunities

Peter J. Hotez et al.

Summary: This article discusses the sources and characteristics of different COVID-19 vaccines, providing a decision-making toolkit to help people consider their available vaccine options.

MICROBES AND INFECTION (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Jocelyn Keehner et al.

Summary: A study showed that while 71% of healthcare workers tested positive for SARS-CoV-2 within 2 weeks after receiving the vaccine, the percentage decreased after the second dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Ezgi Hacisuleyman et al.

Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: US reports low rate of new infections in people already vaccinated

Owen Dyer

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Microbiology

Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection

Morgane Rolland et al.

PLOS PATHOGENS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021

Richard A. Teran et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic RESPONSE

Daniel P. Oran et al.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Letter Infectious Diseases

Genomic survey of SARS-CoV-2 vaccine breakthrough infections in healthcare workers from Kerala, India

J. Beena Philomina et al.

JOURNAL OF INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

H. M. El Sahly et al.

Summary: The mRNA-1273 vaccine demonstrated high efficacy in preventing COVID-19 illness and severe disease, with more than 5 months of protection and a good safety profile, including protection against asymptomatic infection.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Surgery

Are black and Hispanic persons disproportionately affected by COVID-19 because of higher obesity rates?

Maher El Chaar et al.

SURGERY FOR OBESITY AND RELATED DISEASES (2020)

Add to Collection

Review Immunology

COVID-19 Vaccines: Should We Fear ADE?

Scott B. Halstead et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

SARS-CoV-2 reinfection and implications for vaccine development

Firzan Nainu et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 disparity among racial and ethnic minorities in the US: A cross sectional analysis

Raghavendra Tirupathi et al.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Why are RNA virus mutation rates so damn high?

Siobain Duffy

PLOS BIOLOGY (2018)

Add to Collection

© Peeref 2019-2024. All rights reserved.